Cardiovascular

Latest News

Coffee | Image credit: dimakp - stock.adobe.com
Lower Risk of Cardiovascular Disease Mortality Associated With Morning Coffee

January 9th 2025

Americans who drank coffee in the morning had a lower overall mortality compared with those who drank coffee later in the day.

Cardiovascular top 5 of 2024 | Image Credit: Venngage
Top 5 Most-Read Cardiovascular Content of 2024

December 25th 2024

AHA 2024 Highlights
ICYMI: AHA 2024 Scientific Session Highlights

December 20th 2024

Heart pulse, beat concept in atrial fibrillation | image credit: martialred - stock.adobe.com
Q&A: Dr Dan Bloomfield Elaborates on Novel Findings From AZALEA-TIMI 71 Trial, Future of FXI Inhibitor Abelacimab

December 19th 2024

ASCVD | Image credit: Zhanna - stock.adobe.com
Low Lp(a) Testing in ASCVD: Higher Levels in Black and Female Patients

December 17th 2024

Advancements in Population Health Strategies for Cardiovascular Risk Management

Experts discuss how lipoproteins drive atherosclerotic heart disease, review the different guidelines and recommendations on Lp(a) testing, and insights from clinical trials.

Hands holding a heart with a heartbeat on it and the words AJMC Insights
Continuing Medical Education
View All
January 13th 2025

Exploring Transthyretin-Mediated Amyloidosis and Its Phenotypes: A Comprehensive Approach to Patient Treatment

1.5 Credits / Cardiology, Neurology, Rare Diseases
January 13th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
January 13th 2025

Evidence-Based Guidelines Point to Leap in Care for Hypertrophic Cardiomyopathy

1.0 Credit / Cardiology

More News

Site Logo
June 29th 2019

CREDENCE: First Renal Outcomes Trial Finds Canagliflozin Cuts Risk of Renal Failure, Death; Prompts ADA Updates

Mary Caffrey
Presentations at 2 major scientific conferences showed that the SGLT2 inhibitor cut the risk of renal failure or death by 30% and had renal benefits for patients with and without previous cardiovascular disease.
Site Logo
June 29th 2019

Outcomes Trials Set Stage for Future of Diabetes Management in Patients With Renal Disease

Joseph E. Cruz, PharmD, BCPS Mary Bridgeman, PharmD, BCPS, BCGP
Two doctors of pharmacy review the impact of recent outcomes trials for newer classes of type 2 diabetes therapy.
FDA's Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm
June 28th 2019

FDA's Fast Track Designation for Empagliflozin in Heart Failure Points to New Paradigm

Mary Caffrey
The EMPEROR trials could lead to new indications for the SGLT2 inhibitor for patients with and without diabetes.
Site Logo
June 28th 2019

From the Editor-in-Chief: Evolving Role of T2D Therapy, From Secondary to Primary Prevention

Robert A. Gabbay, MD, PhD, FACP
Evidence that newer type 2 diabetes therapies offer cardiovasular and renal benefits offer opportunities for greater collaboration among specialists and more value for patients. Payers must take notice.
Using Real-World Evidence to Understand Disparities, Clinical Inertia
June 18th 2019

Using Real-World Evidence to Understand Disparities, Clinical Inertia

Mary Caffrey
Merck's Center for Observational and Real-World Evidence has spent several years gathering evidence on clinical inertia and is now working on solutions to overcome it at the point of care.
5 Takeaways From the ADA Scientific Sessions
June 14th 2019

5 Takeaways From the ADA Scientific Sessions

Mary Caffrey
There was something for everyone at the American Diabetes Association (ADA) Scientific Sessions, held June 7-11, 2019, in San Francisco, California.
Site Logo
June 12th 2019

More CV, Renal Outcomes at ADA: CREDENCE, CARMELINA, CAROLINA

Mary Caffrey
The final morning session of the 79th Scientific Sessions of the American Diabetes Association (ADA) in San Francisco, California, featured more cardiovascular and renal results from recent trials involving type 2 diabetes drugs.
Site Logo
June 11th 2019

Highlighting Links Between Kidney, CV Disease in Diabetes

Mary Caffrey
The connections among diabetes, cardiovascular (CV) disease, and kidney failure have been a theme of the 79th Scientific Sessions of the American Diabetes Association, which featured a joint session with the American Society of Nephrology.
This Week in Managed Care: May 31, 2019
May 31st 2019

This Week in Managed Care: May 31, 2019

This week, the top managed care news included the FDA's approval of a $2.1 million gene therapy; a study revealing that the worldwide need for palliative care will nearly double by 2060; the FDA granting priority review to Amarin’s Vascepa for a cardiovascular indication.
Site Logo
May 29th 2019

Combining DPP-4 Inhibitor, SGLT2 Inhibitor for Type 2 Diabetes Cost-Effective Over Time, AJMC® Study Says

A Policy article in the May issue of The American Journal of Managed Care® suggests that sequential addition of SGLT2 inhibitors to DPP-4 inhibitors may be considered cost-effective compared with standard treatment using sulfonylurea and insulin for patients with type 2 diabetes who have difficulty maintaining glycated hemoglobin of seven percent or less on metformin alone.
Heart Disease Topped Reasons for Excess Deaths in Puerto Rico After Hurricane Maria
April 19th 2019

Heart Disease Topped Reasons for Excess Deaths in Puerto Rico After Hurricane Maria

Allison Inserro
Heart disease was the number one reason for “excess deaths” after Hurricane Maria struck Puerto Rico in September 2017.
As Comorbidities Pile Up, True Diabetes Cost Measured by More Than Insulin, Panel Says
April 14th 2019

As Comorbidities Pile Up, True Diabetes Cost Measured by More Than Insulin, Panel Says

Allison Inserro
For endocrinologists, a cardiologist, a diabetes educator, and a room full of fellow health workers, the cost of doing nothing—not just to treat diabetes, but also to prevent it— is what feeds into the exorbitant cost of the disease, according to presentations and a panel at the inaugural meeting of the Institute for Value Based Medicine (IVBM) in Diabetes, an initiative of The American Journal of Managed Care®.
Lost Productivity From Heart Attack, Stroke Are Twice Direct Medical Costs, Study Finds
April 9th 2019

Lost Productivity From Heart Attack, Stroke Are Twice Direct Medical Costs, Study Finds

Mary Caffrey
The results come as US professional societies are updating primary prevention guidelines in cardiology.
Site Logo
April 8th 2019

Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population

Maureen J. Lage, PhD
Previous research overstated the generalizability of the Exenatide Study of Cardiovascular Event Lowering trial results by omitting the restriction on the percentage of patients without a prior cardiovascular event.
Site Logo
April 8th 2019

Authors’ Reply to “Comment on Generalizability of GLP-1 RA CVOTs in US T2D Population”

Eric T. Wittbrodt, PharmD, MPH James M. Eudicone, MS, MBA Kelly F. Bell, PharmD, MSPhr Devin M. Enhoffer, PharmD Keith Latham, PharmD Jennifer B. Green, MD
The authors of the manuscript “Generalizability of Glucagon-Like Peptide-1 Receptor Agonist Cardiovascular Outcome Trials Enrollment Criteria to the US Type 2 Diabetes Population” respond to a letter to the editor.
Amarin Files Supplemental NDA With FDA for Vascepa Based on REDUCE-IT Results
April 4th 2019

Amarin Files Supplemental NDA With FDA for Vascepa Based on REDUCE-IT Results

Wallace Stephens
Based on recently published results of the REDUCE-IT study, pharmacuetical company Amarin has submitted a supplemental new drug application (sNDA) to the FDA for an expanded label for its leading drug Vascepa. Also, the American Diabetes Association has included the drug in a mid-year update to its 2019 Standards of Medical Care in Diabetes.
Site Logo
March 31st 2019

EBDM March 2019: Clinical Updates

Mary Caffrey Laura Joszt, MA Kelly Davio
Site Logo
March 28th 2019

Managing Cholesterol With PCSK9 Inhibitors and Overcoming Operational Challenges in Practice

Laura Joszt, MA
Panelists discuss what PCSK9 inhibitors are, the evidence to support them, and challenges with operationalizing them in practice.
Incentivizing Healthy Eating in Medicare, Medicaid Is Cost Effective, Study Finds
March 22nd 2019

Incentivizing Healthy Eating in Medicare, Medicaid Is Cost Effective, Study Finds

Laura Joszt, MA
Researchers found that a prescription for healthy food can improve health outcomes for beneficiaries in Medicare and Medicaid.
5 Takeaways From the 2019 American College of Cardiology Meeting
March 22nd 2019

5 Takeaways From the 2019 American College of Cardiology Meeting

Mary Caffrey
For SGLT2 inhibitors and a fish oil capsule, there was plenty of good news; for aspirin, not so much. A recap of the American College of Cardiology's 68th Annual Scientific Session, held March 16-18, 2019, in New Orleans, Louisiana.
Novo Nordisk Seeks Oral Semaglutide Approval, CV Indications on New Drug and Injectable
March 21st 2019

Novo Nordisk Seeks Oral Semaglutide Approval, CV Indications on New Drug and Injectable

Mary Caffrey Samantha DiGrande
If approved the oral form of semaglutide would be the first pill in the GLP-1 receptor agonist class.
Site Logo
March 18th 2019

Amarin's High-Dose Fish Oil Pill Cuts Total CV Event Risk 30% in Study

Mary Caffrey
New results presented at the American College of Cardiology's 68th Annual Scientific Session find a high-dose fish oil pill reduced the risk for first and future cardiovascular events among patients taking statins by 30%. The early results grabbed headlines last fall in part because researchers aren't entirely sure how the capsule works.
Site Logo
March 18th 2019

DECLARE: Dapagliflozin Offers Benefits for Diabetes Patients With Heart Failure

Mary Caffrey
New findings show reduced hospitalizations for a wide group of patients with heart failure. For high-risk patients with reduced ejection fraction, the drug appears to cut deaths, but more studies will answer these questions.
Site Logo
March 17th 2019

Cardiovascular Prevention Guidelines Call for Less Aspirin, More SGLT2s, GLP-1s for Type 2 Diabetes

Mary Caffrey
The joint guidelines from the American College of Cardiology and the American Heart Association call on clinicians to pay more attention to social determinants of health. They were announced Sunday at the 68th Scientific Session of the American College of Cardiology in New Orleans, Louisiana.
Site Logo
March 16th 2019

Giant Study Suggests Apple Watch Accurately Catches Atrial Fibrillation

Mary Caffrey
The 68th American College of Cardiology Scientific Session and Exposition opens with a study that suggests the Apple Watch can detect atrial fibrillation with a reasonable degree of accuracy, giving people an opportunity to get in touch with their doctor before a serious event like a stroke.
From the Apple Watch to Heart Failure at Annual Cardiologists' Meeting
March 16th 2019

From the Apple Watch to Heart Failure at Annual Cardiologists' Meeting

Mary Caffrey
In recent years, the big news on the first day of the American College of Cardiology (ACC) Scientific Session and Exposition has involved a therapy—usually an expensive cholesterol drug with a name almost no one could pronounce: proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. This year, it's tech, and an easy-to-pronounce name: Apple.
What We're Reading: Flu Shot During Pregnancy; Liquid Biopsy for NSCLC; Physician-Generated Revenue
February 28th 2019

What We're Reading: Flu Shot During Pregnancy; Liquid Biopsy for NSCLC; Physician-Generated Revenue

AJMC Staff
Researchers have confirmed that there is no link between flu shots and miscarriages; a liquid biopsy is as effective as tissue-based testing for identifying treatment for lung cancer; and physicians generate an average of $2 million a year for hospitals.
Even Among the Insured, Patients With Cardiovascular Disease Face Financial Toxicity
February 13th 2019

Even Among the Insured, Patients With Cardiovascular Disease Face Financial Toxicity

Kelly Davio
Atherosclerotic cardiovascular disease (ASCVD) is not only a leading cause of mortality among US adults, but also responsible for high medical costs that burden both the healthcare system and individual patients. New research shows that 1 in every 5 patients with ASCVD is unable to afford his or her medical bills, and even among patients with insurance, financial hardship related to medical costs is prevalent.
2018 American College of Cardiology ECDP Encourages Collaboration Among Specialists and PCPs
February 7th 2019

2018 American College of Cardiology ECDP Encourages Collaboration Among Specialists and PCPs

The American Journal of Managed Care® (AJMC®) recently spoke with Om P. Ganda, MD, medical director of the Lipid Clinic and chair of the Clinical Oversight Committee at the Joslin Diabetes Center in Boston, Massachusetts, about the recent publication of the 2018 American College of Cardiology (ACC) Expert Consensus Decision Pathway (ECDP).1
SGLT2 Inhibitors and GLP-1 Agonists Have the Potential to Change the Type 2 Diabetes Treatment Paradigm. Will That Be Embraced?
January 31st 2019

SGLT2 Inhibitors and GLP-1 Agonists Have the Potential to Change the Type 2 Diabetes Treatment Paradigm. Will That Be Embraced?

AJMC Staff
Javed Butler, MD, MPH, MBA, discusses the 2018 American College of Cardiology Expert Consensus Decision Pathway, which includes guidance on the use of SGLT2 inhibitors and GLP-1 receptor agonists, and its potential to change the treatment paradigm for patients with type 2 diabetes.
<1
...
456789101112
...
22>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo